These cells preferentially express CCR4 (believed to have a major role in the recruitment of Tregs to the TME), which is being targeted with an anti-CCR4 monoclonal antibody, mogamulizumab, in different tumor types, including HNSCC. The gene discussed is CCR4; the disease is head and neck squamous cell carcinoma.